Skip to main content

Tagged With "Palforzia"

Blog Post Featured

Breaking News: FDA Approves Palforzia, a Ground-Breaking Peanut Allergy Oral Immunotherapy Treatment

KFA News Team ·
On Jan. 31, 2020, the U.S. Food and Drug Administration (FDA) announced its approval of Aimmune Therapeutics’ peanut treatment, Palforzia, for children ages 4 to 17. This is big news for the food allergy community. Food allergies put a significant mental, social and financial burden on families. Until now, strict avoidance has been the only way to avoid allergic reactions. Palforzia may give many families managing peanut allergies more freedom and greater quality of life.
Blog Post Featured

AAFA Brings Patient Voice to FDA Committee Review on Palforzia, Oral Immunotherapy Treatment for Peanut Allergy

Kids With Food Allergies ·
On Sept. 13, 2019, the U.S. Food and Drug Administration’s (FDA) Allergenic Products Advisory Committee recommended the approval of Aimmune Therapeutics’ peanut treatment, Palforzia. If approved, Palforzia would be ground-breaking for the future of food allergy treatments. What Is Palforzia? Palforzia, also known as AR101, is a type of oral immunotherapy (OIT) for peanut allergy. If approved, it would be the first FDA-approved treatment for peanut allergy. Currently, some allergists already...
Blog Post

Parenting + Food Allergies: The Social, Emotional and Financial Impact on Families (Video)

Kids With Food Allergies ·
On Sept. 26, 2019, Kenneth Mendez, CEO and president of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with blogger Deva Dalporto of MyLifeSuckers. If you didn’t have a chance to tune in live, you can watch a replay of session. Kids With Food Allergies (KFA) is a division of AAFA.
Comment

Re: Breaking News: FDA Approves Palforzia, a Ground-Breaking Peanut Allergy Oral Immunotherapy Treatment

A-Ma ·
Curious what folks are finding (beyond clinical trials) in side effects, symptoms, success and failures with kids with multiple food allergies
Blog Post

Study Shows Children Who Took PALFORZIA® Peanut Allergy Treatment Daily for Two Years Could Tolerate Higher Doses of Peanut

KFA News Team ·
Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced the publication of a longitudinal analysis that explored the safety, efficacy and food allergy-related quality of life of long-term treatment with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp, previously known as investigational agent AR101] in patients with peanut allergy.
Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
1235 South Clark Street Suite 305, Arlington, VA 22202
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×